Co-Authors
This is a "connection" page, showing publications co-authored by Everett E. Vokes and Mark Kozloff.
Connection Strength
0.763
-
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
Score: 0.118
-
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
Score: 0.101
-
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
Score: 0.084
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.081
-
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):245-51.
Score: 0.068
-
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
Score: 0.067
-
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32.
Score: 0.061
-
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol. 2004 Mar 15; 22(6):1110-7.
Score: 0.060
-
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048.
Score: 0.054
-
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
Score: 0.026
-
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
Score: 0.022
-
Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
Score: 0.022